NYSE · AORT
Artivion, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AORT: Nov 05, 2026
Artivion, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $0.11. The reported EPS for the same quarter last year was $0.16.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.11 | $0.11 | $0.11 | 1 |
| Dec 2026 | $0.13 | $0.13 | $0.13 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · MarketBeat · RTTNews- Zacks · Oct 27, 5:20 PM EDTOrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue EstimatesOrthoPediatrics (KIDS) delivered earnings and revenue surprises of +8.00% and +6.01%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- The Motley Fool · Aug 13, 8:46 PM EDTArtivion (AORT) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 7, 6:04 PM EDTArtivion Q2 Earnings Call HighlightsArtivion (NYSE:AORT) reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA
- Zacks · Aug 6, 5:40 PM EDTArtivion (AORT) Q2 Earnings Meet EstimatesArtivion (AORT) delivered earnings and revenue surprises of 0.00% and +4.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 6:10 PM EDTSteris (STE) Q1 Earnings Surpass EstimatesSteris (STE) delivered earnings and revenue surprises of +1.97% and -0.83%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 16, 5:15 PM EDTIntuitive Surgical, Inc. (ISRG) Q2 Earnings and Revenues Top EstimatesIntuitive Surgical (ISRG) delivered earnings and revenue surprises of +12.90% and +3.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 2, 10:09 AM EDTWeekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal(RTTNews) – The holiday-shortened week delivered no shortage of action for the biotech sector, with a mix of FDA, China, Canada, and EU approvals, acquisitions, and positive clinical readouts, alongside regulatory rejections, program discontinuations, and trial goal misses.
- Zacks · Jul 1, 10:12 AM EDTArtivion Secures FDA Approval for AMDS Hybrid Prosthesis DeviceAORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
- RTTNews · Jun 29, 11:39 AM EDTArtivion Gains FDA PMA Approval For AMDS Hybrid Prosthesis In Treating Aortic Dissections(RTTNews) – Artivion Inc. (AORT), a cardiac and vascular surgery company, on Monday reported receipt of premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for the AMDS Hybrid Prosthesis in the treatment of Debakey Type 1 aortic dissections.
- RTTNews · Jun 29, 8:25 AM EDTArtivion Wins FDA Approval For AMDS Hybrid Prosthesis(RTTNews) – Artivion, Inc. (AORT), a medical device company, on Monday said the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for AMDS Hybrid Prosthesis, a device used to treat acute DeBakey Type I aortic dissections.
- BNK Invest · Jun 18, 4:40 PM EDTOversold Conditions For Artivion (AORT)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- The Motley Fool · May 17, 4:51 PM EDTCrafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top HoldingAcquired 634,223 shares in Artivion; estimated trade size $25.02 million based on quarterly average price
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Artivion, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.